| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
|
ASLAN003 is a novel, potent and orally bioavailable inhibitor of DHODH (Human Dihydroorotate Dehydrogenase) which has the potential to be first-in-class in AML (Acute Myelogenous Leukemia). ASLAN003 has antitumor activity.
| ln Vitro |
For 48 hours, farudodstat (0.01-100 μM) suppresses the growth of leukemia cells. 50% or more of the cell viability is maintained at concentrations of Farudodstat [1]. Cleaved caspase 8 is considerably increased by farudodstat (0.5, 1 μM) for 48 hours [1]. Farudodstat (2, 4 μM; for 96 hours) decreases viability and causes differentiation in myelodysplastic syndrome samples and primary acute myeloid leukemia blasts [1]. It was demonstrated that in MOLM-14 and KG-1 cells, fardodstat (1, 2 μM; 1 hour pretreatment before OPP, 1 hour on) slows protein synthesis and decreases incorporation of O-propargylpuromycin (OPP) into protein translation sites. RPL6 and EIF4B protein downregulation is brought on by farudodstat [1].
|
|---|---|
| ln Vivo |
The number of disseminated tumors is significantly decreased and survival is prolonged when farudstat (50 mg/kg; oral gavage; once daily; days 3 to 30) is administered [1].
|
| Cell Assay |
Cell Proliferation Assay[1]
Cell Types: THP-1, MOLM-14 and KG-1 Cell Tested Concentrations: 0.01, 0.1, 1, 10, 100 μM Incubation Duration: 48 hrs (hours) Experimental Results: THP-1, MOLM-14 and KG- 1 Cell Inhibition of Leukemia Cell Proliferation The IC50 values of MOLM-14 and KG-1 are 152 nM, 582 nM and 382 nM respectively. Western Blot Analysis[1] Cell Types: KG-1 and MOLM-14 Cell Tested Concentrations: 0.5, 1 μM Incubation Duration: 48 hrs (hours) Experimental Results: Significant increase in cleaved caspase 8 and leakage of cytochrome c from mitochondria into the cytosol and induces cleavage of caspase-3 and -7. |
| Animal Protocol |
Animal/Disease Models: Female NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ, NGS mice (4-6 weeks old) with MOLM-14 cells [1]
Doses: 50 mg/kg Route of Administration: po (oral gavage); one time/day; Results from day 3 to day 30: The number of disseminated tumors and tumor size were Dramatically diminished. Survival period was Dramatically prolonged. |
| References |
[1]. Jianbiao Zhou, et al. ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. Haematologica. 2019 Nov7;haematol.2019.230482.
[2]. Marco L. Lolli, et al. Human Dihydroorotate Dehydrogenase (hDHODH) as a new target on Acute Myelogenous Leukemia (AML): Targeting Myeloid Differentiation using Potent and Innovative hDHODH Inhibitors. 23rd Swedish Conference on Macromolecular Structure an |
| Molecular Formula |
C₁₉H₁₄F₂N₂O₃
|
|---|---|
| Molecular Weight |
356.322871685028
|
| CAS # |
1035688-66-4
|
| SMILES |
O=C(C1=CC=CN=C1NC2=C(F)C=C(C3=CC=CC(OC)=C3)C=C2F)O
|
| InChi Key |
OMPATGZMNFWVOH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C19H14F2N2O3/c1-26-13-5-2-4-11(8-13)12-9-15(20)17(16(21)10-12)23-18-14(19(24)25)6-3-7-22-18/h2-10H,1H3,(H,22,23)(H,24,25)
|
| Chemical Name |
2-((3,5-difluoro-3'-methoxy-[1,1'-biphenyl]-4-yl)amino)nicotinic acid
|
| Synonyms |
ASLAN003 ASLAN 003 ASLAN-003 Aslan-003.
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~350.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.17 mg/mL (6.09 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.17 mg/mL (6.09 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 21.7 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8065 mL | 14.0323 mL | 28.0647 mL | |
| 5 mM | 0.5613 mL | 2.8065 mL | 5.6129 mL | |
| 10 mM | 0.2806 mL | 1.4032 mL | 2.8065 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
